Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity
Journal of Enzyme Inhibition and Medicinal Chemistry · 2023
DOI: 10.1080/14756366.2023.2189097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. Verfasst von Ashraf K El-Damasy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Pyrimidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Science & Technology, Korean government, Institutional Program grant by the Korea Institute of Science and Technology.
Abstract (Originalsprache)
The design of kinase inhibitors targeting the oncogenic kinase BCR-ABL constitutes a promising paradigm for treating chronic myeloid leukaemia (CML). Nevertheless, the efficacy of imatinib, the first FDA-approved targeted therapy for CML, is curbed by the emergence of resistance. Herein, we report the identification of the 2-methoxyphenyl ureidobenzothiazole AK-HW-90 (2b) as a potent pan-BCR-ABL inhibitor against imatinib-resistant mutants, particularly T315I. A concise array of six compounds 2a-f was designed based on our previously reported benzothiazole lead AKE-5l to improve its BCR-ABLT315I inhibitory activity. Replacing the 6-oxypicolinamide moiety of AKE-5l with o-methoxyphenyl and changing the propyl spacer with phenyl afforded 2a and AK-HW-90 (2b) with IC50 values of 2.0 and 0.65 nM against BCR-ABLT315I, respectively. AK-HW-90 showed superior anticancer potency to imatinib against multiple cancer cells (NCI), including leukaemia K-562. The obtained outcomes offer AK-HW-90 as a promising candidate for the treatment of CML and other types of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Center for Supercomputing Applications, Div. of National Supercomputing R&D, Korea Institute of Science and Technology Information, Daejeon, Republic of Korea.
- Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
- Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Republic of Korea.
Förderung
- National Research Council of Science & Technology
- Korean government
- Institutional Program grant by the Korea Institute of Science and Technology
- the Korea Research Fellowship Program grant through NRF funded by the Ministry of Science and ICT
- Korea Institute of Science and Technology Information (KISTI) Institutional Program
- National Cancer Institute
Zitieren
APA
El-Damasy, A. K., Jin, H., Park, J. W., Kim, H. J., Khojah, H., Seo, S. H., Lee, J. H., Bang, E. K., & Keum, G. (2023). Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2189097
Vancouver
El-Damasy AK, Jin H, Park JW, Kim HJ, Khojah H, Seo SH, et al. Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023. doi:10.1080/14756366.2023.2189097
BibTeX
@article{ElDamasy2023,
author = {El-Damasy, Ashraf K and Jin, Heewon and Park, Jung Woo and Kim, Hyun Ji and Khojah, Hanan and Seo, Seon Hee and Lee, Ju-Hyeon and Bang, Eun-Kyoung and Keum, Gyochang},
title = {Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2023},
doi = {10.1080/14756366.2023.2189097}
}
EUVIMED